Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O95843
UPID:
GUC1C_HUMAN
Alternative names:
Guanylate cyclase activator 1C
Alternative UPACC:
O95843; O95844; Q9UNM0
Background:
Guanylyl cyclase-activating protein 3, also known as Guanylate cyclase activator 1C, plays a pivotal role in visual signal transduction. It modulates guanylyl cyclase 1 (GC1) and GC2 activity in response to changes in free calcium ions concentration, facilitating the recovery of rod photoreceptors to the dark state after light exposure.
Therapeutic significance:
Understanding the role of Guanylyl cyclase-activating protein 3 could open doors to potential therapeutic strategies.